I am absolutely delighted and relieved to report that Regorafenib is now officially back on the cancer drugs fund for GIST patients in England.
In a statement released today the NHS said:
In December, the national CDF Panel took a careful look at how we ensure the drugs available offer the best clinical benefit, getting the most for patients from every pound. Following this prioritisation process, drug manufacturers had the opportunity to request that the Cancer Programme of Care Board review their case. The review looked at whether the Standard Operating Procedures, on which we publicly consulted, were fully followed. It did not look at the medical decisions made by doctors on the national CDF Panel.
The Board referred five of these back to the CDF panel to review at the last panel meeting, which were also considered alongside new applications for inclusion in the CDF in the normal way.
After careful consideration, one of the five drug indications that were looked at again will remain on the CDF (Regorafenib).
All I can say is thank you all for your support, efforts and kind words, it wasn’t in vain… oh and of course one last BOOOM!